Learn the research updates and medical news for rheumatic diseases from the European Congress of Rheumatology 2021.
New research shows that biologic medications can slow the progression of sacroiliac joint damage in axial spondyloarthritis (axSpA) patients, but it can take more than two years to see the benefits.
The news is reassuring for arthritis and rheumatic disease patients who have been concerned about the potential risk of post-vaccine disease flares.
Recent advances in rheumatoid arthritis treatment have made it possible to slow the disease’s progression and, in turn, reduce the risk of other inflammatory-related problems, like heart disease and dementia.
On the other hand, study authors did not find an association between using other biologics — such as TNF inhibitors, IL-6 inhibitors, and abatacept — and worse COVID-19 outcomes.
A new study from the ArthritisPower research registry found that more than 60 percent of axial spondyloarthritis (axSpA) patients on biologics said their treatment wore off before the next dose, which negatively impacted their disease activity and sleep.
A new study from the ArthritisPower research registry found that following a mindfulness therapy program may help patients with rheumatic diseases, like osteoarthritis and rheumatoid arthritis, decrease their anxiety and stress levels.
A new study from the ArthritisPower research registry found that psoriatic arthritis (PsA) greatly impacts patients' ability to be physically active and live independently, and they want their treatment plan to help improve those aspects of life.